These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14632547)

  • 1. Comment: venous thromboembolism prophylaxis conversion in nonsurgical inpatients.
    Fanikos J; Tsilimingras K
    Ann Pharmacother; 2003 Dec; 37(12):1914-5; reply 1916-7. PubMed ID: 14632547
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment: venous thromboembolism prophylaxis conversion in nonsurgical inpatients.
    Groce JB
    Ann Pharmacother; 2003 Dec; 37(12):1915-6; reply 1916-7. PubMed ID: 14632546
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
    McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
    Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparins, low-molecular-weight heparins, and pentasaccharides.
    Dinwoodey DL; Ansell JE
    Clin Geriatr Med; 2006 Feb; 22(1):1-15, vii. PubMed ID: 16377464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of venous thromboembolism in internal medicine and neurology].
    Malý J; Dulícek P; Penka M; Malý R; Gumulec J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
    Hull RD; Pineo GF
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin and angiogenesis: size matters!
    Rak J; Weitz JI
    Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):1954-5. PubMed ID: 14617616
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
    Brewer D
    Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
    [No Abstract]   [Full Text] [Related]  

  • 10. Venous thromboembolism prophylaxis and treatment in patients with acute stroke and traumatic brain injury.
    Vergouwen MD; Roos YB; Kamphuisen PW
    Curr Opin Crit Care; 2008 Apr; 14(2):149-55. PubMed ID: 18388676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The optimal long-term treatment of venous thromboembolism.
    Prandoni P
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):729-32. PubMed ID: 16170889
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of thromboembolism in pregnancy.
    Marks PW
    Semin Perinatol; 2007 Aug; 31(4):227-31. PubMed ID: 17825678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
    Wein L; Wein S; Haas SJ; Shaw J; Krum H
    Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
    Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
    Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism and cancer: prevention and therapy.
    Lee AY
    Vnitr Lek; 2006 Mar; 52 Suppl 1():127-8, 130-1. PubMed ID: 16637461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of thromboembolism and its modulation by low molecular weight heparins.
    Breddin HK
    Semin Thromb Hemost; 1993; 19 Suppl 1():227-8. PubMed ID: 8395726
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.
    Själander A; Jansson JH; Bergqvist D; Eriksson H; Carlberg B; Svensson P
    J Intern Med; 2008 Jan; 263(1):52-60. PubMed ID: 18088252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparin in pregnancy: current issues.
    Greer I; Hunt BJ
    Br J Haematol; 2005 Mar; 128(5):593-601. PubMed ID: 15725079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparin as bridging anticoagulation.
    van Dongen CJ; Vink R; Levi M
    Arch Intern Med; 2004 Dec 13-27; 164(22):2500. PubMed ID: 15596646
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
    Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
    J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.